妊娠期益生菌补充对子痫前期及母亲、胎儿和新生儿相关结局影响的系统评价与荟萃分析
该系统评价与荟萃分析纳入29项随机对照试验共7735名孕妇,评估妊娠期益生菌补充对子痫前期及母婴结局的影响。益生菌对子痫前期风险可能无差异(RR 1.14,95%CI 0.84-1.53,低确定性证据),对早产和分娩孕周也可能无差异。结论认为证据有限,需进一步高质量试验。
要点
- 益生菌对子痫前期风险可能无差异(RR 1.14,95%CI 0.84-1.53,低确定性证据)。
- 益生菌对<37周早产可能无差异(RR 0.93,95%CI 0.66-1.30,低确定性证据)。
- 益生菌对分娩孕周可能无差异(均差-0.03周,95%CI -0.16至0.10周,低确定性证据)。
核心结论
- 有限证据提示益生菌补充不影响子痫前期风险,需进一步高质量试验明确其获益与可能危害。
研究设计与样本
- 系统评价与荟萃分析,检索Ovid MEDLINE、Embase、CINAHL、Cochrane、Global Index Medicus和Maternity and Infant Care Database共6个数据库,从建库至2023年8月2日。
- 纳入29项随机对照试验共7735名孕妇,评估妊娠任何阶段益生菌补充的效果。
- 方案注册号CRD42023421613,两名作者独立评估纳入、提取数据、使用ROB-2工具评估偏倚风险并采用GRADE评级。
主要发现
- 益生菌对子痫前期风险可能无差异(RR 1.14,95%CI 0.84-1.53;11项试验,2401名妇女;低确定性证据)。
- 益生菌对<37周早产可能无差异(RR 0.93,95%CI 0.66-1.30;18项试验,4016名妇女;低确定性证据)。
- 益生菌对分娩孕周可能无差异(均差-0.03周[约0.2天],95%CI -0.16至0.10周[约-1.1至0.7天];13项试验,2194名妇女;低确定性证据)。
- 其他次要结局因证据确定性极低难以评估,但未观察到获益或危害。
关键数值与推荐
- 主要结局为子痫前期、子痫和母亲死亡的发生率。
- 试验间纳入人群和测试的益生菌类型存在异质性,共20种不同菌株,但多数为口服给药。
临床怎么用
- 原文未据此给出推荐,仅指出有限证据提示益生菌补充不影响子痫前期风险,需进一步高质量试验评估获益与可能危害。
局限性
- 试验间纳入人群和测试的益生菌类型存在异质性,共20种不同菌株,但多数为口服给药。
- 其他次要结局证据确定性极低,难以评估益生菌对其的影响。
- 缺乏纳入营养不良或微生物失调妇女的试验数据,而益生菌补充对这些人群可能有用。
- 需进一步高质量试验明确益生菌补充的获益与可能危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to synthesize the available evidence on probiotic administration during pregnancy for the prevention of preeclampsia and its effects on related maternal, fetal, and newborn outcomes. DATA SOURCES: Six databases were systematically searched for eligible studies, namely Ovid MEDLINE, Embase, CINAHL, Cochrane, Global Index Medicus, and the Maternity and Infant Care Database, from inception to August 2, 2023. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials that evaluated the effects of probiotic administration on women during any stage of pregnancy were eligible for inclusion. METHODS: The protocol was registered with the International Prospective Register of Systematic Reviews under identifier CRD42023421613. Evaluating study eligibility, extracting data, assessing risk of bias (ROB-2 tool), and rating certainty (Grading of Recommendations, Assessment, Development and Evaluations) were conducted independently by 2 authors. The primary outcomes were incidence of preeclampsia, eclampsia, and maternal mortality. A meta-analysis was performed, and the results were reported as risk ratios with 95% confidence intervals. RESULTS: A total of 29 trials (7735 pregnant women) met the eligibility criteria. There was heterogeneity across the trials in the population of enrolled women and the type of probiotic tested (20 different strains), although most used oral administration. Probiotics may make no difference to the risk of preeclampsia (risk ratio, 1.14; 95% confidence interval, 0.84-1.53; 11 trials; 2401 women; low certainty evidence), preterm birth at <37 weeks' gestation (risk ratio, 0.93; 95% confidence interval, 0.66-1.30; 18 trials, 4016 women; low certainty evidence), or gestational age at delivery (mean difference, -0.03 weeks [≈0.2 days]; 95% confidence interval, -0.16 to 0.10 weeks [≈ -1.1 to 0.7 days]; 13 trials, 2194 women; low certainty evidence). It is difficult to assess the effects of probiotics on other secondary outcomes because the evidence was of very low certainty, however, no benefits or harms were observed. CONCLUSION: Limited evidence suggests that probiotic supplementation does not affect the risk for preeclampsia. Further high-quality trials are needed to definitively assess the benefits and possible harms of probiotic supplementation during pregnancy. There is also a lack of data from trials that included women who were undernourished or who experienced microbial dysbiosis and for whom probiotic supplementation might be useful.
引用
- McDougall A, Nguyen R, Nguyen PY, et al. The effects of probiotics administration during pregnancy on preeclampsia and associated maternal, fetal, and newborn outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2024. PMID: 38447676. doi:10.1016/j.ajogmf.2024.101322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。